Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir? - Wikidata - wikimedia - TriplyDB

Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?

Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?

http://www.wikidata.org/entity/Q36827134

about

Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?

http://www.wikidata.org/entity/Q36827134

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?

@en

type

label

Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?

@en

prefLabel

Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?

@en

P1433

Q36827134-53785237-1B87-4D26-B912-000A213B5E7D

P1476

Q36827134-8AF428C5-6786-4880-8CA2-4A76B323C94D

P2093

Q36827134-48CFEBD6-0A14-4339-802E-78C8EC542A26

Q36827134-6AAC2F55-CEBE-4F2C-BF3A-4508689229AD

Q36827134-9DB5B7BC-E056-4DD6-8B3E-2ABD5B926F34

P2860

Q36827134-055E25DF-C573-402C-A69F-6F61E70CEB47

Q36827134-06D78662-4E82-4EA7-ACD9-665D8B45681D

Q36827134-06FFC2EE-2468-417F-92F4-6CEC7EA8EEF3

Q36827134-0768B6E6-2CA6-44A1-87A2-FCBE1276AA68

Q36827134-090B252B-09A8-45BF-A5CE-5EC40C8D9598

Q36827134-0E13B3BC-777D-496C-9D88-BE9AB3C7A224

Q36827134-0FCD92F6-7A34-4C89-8CC3-AEAA3D8FA19E

Q36827134-12D37844-FA83-4E63-920F-41611DAEC9D9

Q36827134-136499E5-9B4F-4793-9AC7-4940F86E4A57

Q36827134-14A17644-B117-4FC1-9F0E-83A85A3333EB

P31

Q36827134-F190F69E-62E1-4008-BC19-8E7BA83A7B27

P356

Q36827134-C92768A6-C2CA-4A41-9006-831B004A923E

P433

Q36827134-A4C846F1-3DF5-4F40-8DEF-D3C3DF1D0A26

P478

Q36827134-0864CA6A-D504-42C2-9B56-DBE46A9DB130

P577

Q36827134-DB0159EF-F227-4279-B72D-6F836C4B110A

P698

Q36827134-CE8310B0-0F1F-40EA-88C1-73726AFF67B8

P932

Q36827134-07E1C9D1-595C-436D-9031-6ED719A3A84A

P356

P1433

Immunotherapy (Los Angeles, Calif.)

P1476

Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?

@en

P2093

Asifa Zaidi

http://www.w3.org/2001/XMLSchema#string

Daniel Popkin

http://www.w3.org/2001/XMLSchema#string

Qinglai Meng

http://www.w3.org/2001/XMLSchema#string

P2860

Controlling HIV-1: Non-Coding RNA Gene Therapy Approaches to a Functional Cure

A brief history of the global effort to develop a preventive HIV vaccine

Emerging strategies to deplete the HIV reservoir

T cell engineering as therapy for cancer and HIV: our synthetic future

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production

Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation

CD4+ count-guided interruption of antiretroviral treatment

P31

scholarly article

P356

10.4172/IMT.1000104

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27110598

http://www.w3.org/2001/XMLSchema#string

P932

4841618

http://www.w3.org/2001/XMLSchema#string